Laboratory Response Network Sentinel Laboratories Elizabeth A. Macias, Ph.D., D(ABMM)

Laboratory Response Network Sentinel

LaboratoriesElizabeth A. Macias, Ph.D., D(ABMM)Gatekeeper, Air Force LRN LaboratoriesAir Force Institute for Operational HealthEpidemiological Surveillance Division

(AFIOH/SDE)Brooks City-Base, TX

What is the Laboratory Response Network ?

Laboratory Response Network (LRN)

• Established in 1999 by the Centers for Disease Control and Prevention (CDC)

• Integrated network of laboratories – state and local public health, hospital, military, veterinary, and international

• Respond quickly to biological and chemical terrorism, as well as emerging infectious diseases and other public health threats

LRN Structure

August 2007 - National Laboratory Response Network Policy Letter

• Discusses definition of Basic and Advanced Sentinel laboratories

• “AFMS laboratories will have the CDC technical protocols, notification procedures, and procedures to properly ship clinical samples in place by 1 October 2007…”

AF LRN

If you perform routine diagnostic Microbiology cultures, then you are a Sentinel laboratory.

Minimum requirements:

- Follow BSL-2 guidelines- Plate cultures on blood and chocolate agar- Microscopy capability (Gram stains, wet

mounts)

LRN Sentinel Laboratories

• Recognize, rule-out, and refer to Reference or National laboratories for further testing

LRN Sentinel Laboratories

• Perform testing on clinical specimens, not environmental samples

• Presumptive testing - protocols on American Society for Microbiology (ASM) website http://www.asm.org/Policy/index.asp?bid=6342

LRN Structure

Basic SentinelClinical

Laboratory

Advanced SentinelClinical Laboratory

LRN Sentinel Labs

Serve as “sentinels” for early detection of an agent that cannot be ruled out as a possible bioterrorism-associated organism

Must utilize standardized testing protocols designed to utilize conventional tests to facilitate the “rule out” or “referral” of suspicious isolates to an LRN Reference lab

ASM website: http://www.asm.org/Policy/index.asp?bid=6342

LRN Sentinel Labs

LRN Sentinel Labs

LRN Sentinel Labs

Sentinel labs should not accept environmental (powders, letters, packages), animal, food, or water specimens for examination, culture, or transport for bioterrorism-associated agents

Such specimens should be submitted directly to the nearest LRN Reference laboratory.

LRN Sentinel Labs

X

Very likely that the lab will not be contacted in advance and informed that one of the potential agents of bioterrorism is suspected in the patients’ specimens

LRN Sentinel Labs – Important Reminders

Essential that appropriate safeguards are taken including:

• All blood cultures should be subcultured in a biosafety cabinet

• Follow flowcharts for suspicious agents

• Always considering the possibility of bioterrorist agents.


Your lab should know how to assist clinicians in the diagnosis and management of patients who have been overtly or covertly exposed to a BT agent by:

• Promptly providing accurate information on the selection and collection specimens


• Handle these specimens in a manner that will result in the greatest probability of success in establishing a diagnosis

Your lab must know how to…

- Collect proper specimens- Store and transport specimens at

proper temperatures to ensure stability


• Minimize exposure of hospital personnel and patients to infectious agents

Your lab must know how to…

- Proper PPE- Lab safety- Proper packaging and transport of

specimens


In a suspected or confirmed BT event, immediate and effective communication is imperative

You should notify:

• Appropriate institutional and medical personnel

• Designated BT coordinator (usually PHO or Infection Control


The Sentinel laboratory is NOT responsible for and SHOULD NOT make the decision that a BT event has occurred

That responsibility rests with local, state, and federal health and law enforcement officials


NOTE: Certain geographic areas are known to have natural human cases of infection due to BT agents. For example:

• Tularemia in Nantucket and Martha’s Vineyard, Massachusetts, as well as Missouri, Oklahoma, and neighboring areas

• Plague in much of the southwestern United States, especially New Mexico


COLLEGE OF AMERICAN PATHOLOGY PROFICIENCY

TESTING (CAP PT)

2007 “Laboratory Preparedness Survey” (LPS)

2008 “Laboratory Preparedness Exercise”

(LPX)

CAP Laboratory Preparedness PT

• Developed as a collaborative effort between CAP, CDC, and APHL

• Tests the preparedness of labs across the U.S. to handle potential PH emergencies related to BT agents

• Labs are sent live organisms that exhibit characteristics of BT agents and expected to respond following LRN protocols

Excerpt from 2008 CAP PT catalog

• All agents are excluded from the CDC’s select agent list

• May include strains of B. anthracis, Y. pestis, F. tularensis, and B. abortus that have been modified and are safe for testing in a lab that contains a certified, properly functioning Class II Biological Safety Cabinet (BSC) and is capable of handling Category A and B agents


Excerpt from 2008 CAP PT catalog

Placing an order for the Lab Preparedness PT requires a signature by the Laboratory Director on a “Certificate of Acceptance” form


• “I have reviewed the list of potential organisms to be provided …”

• “Our facility has a properly functioning, certified Class II BSC and we are capable of handling Category A and B agents….”

CAP PT – LPS-B 2007

Biohazard Warning –

p.1, bold font

LPS – B, Shipped October 2007 Kit Instructions state on page 1, “Biohazard Warning”:


• Your lab must have a properly functioning Class II Biological Safety Cabinet in order to participate in this Survey

• All specimens in this Survey should be handled in a Biological Safety Cabinet with BSL-3 primary barriers and safety equipment

Biohazard Warning (continued):


• These strains are attenuated but they represent potentially dangerous pathogens and should be handled as if they are capable of transmitting disease.

• Participants should wear gloves and protective clothing with a solid-front and perform all manipulations in a Class II BSC

Biohazard Warning (continued):


• Additional information on laboratory safety and agent specific precautions can be found on the CDC website: http://www.cdc.gov/od/ohs/biosfty/biosfty.htm


All five specimens (LPS06 – LPS10) had the following for testing instructions: “Labs are instructed to follow the LRN procedures to rule out or refer potential BT agents….”


• Bottom line: Labs were notified up front that these were potential BT agents

• More often than not, we will not have that happen with actual clinical specimens.

Brucella Exposure Overview

• CAP LPS-B survey sent 15 Oct 2007

• CDC notified on 27 Nov by the New York State Dept of Health (NYSDOH) of potential exposures to the Brucella RB51 strain during the LPS exercise

• Exposure initially occurred after a RB51 specimen was mislabeled as a routine patient specimen and submitted to the NYSDOH lab


• Personnel (24) exposed in the NYSDOH lab

• Survey conducted by NYSDOH of their sentinel labs determined that 17 LPS participating labs did not handle the survey correctly

• As of 14 January, 2008, follow up in labs across the U.S. identified a total of 916 lab workers in 254 labs with potential RB51 exposure


• Improper shipping and handling of isolates• Subculturing of isolates on routine lab

bench• Sniffing subcultures• Setting up susceptibility tests on routine

bench• Spilling blood culture bottles• Aerosol generation from ruptured centrifuge

tubes

Some examples of how the exposures occurred:

• Brucella abortus RB51 is an attenuated veterinary vaccine strain that rarely causes infections in humans

• Risk assessment tools, post-exposure prophylaxis and follow up guidelines were sent to LRN sentinel labs


• Read all PT kit instructions

• Emphasize adherence to biosafety practices

Lessons Learned

Annual biosafety training+ +

Include proper use of biosafety cabinet Frequent spot checks to ensure personnel

are using PPE and safety equipment properly

Perform risk assessments if you isolate a highly pathogenic organism (i.e., Brucella or Francisella)

Lab readiness should include training in the characteristics of particular agents (i.e., Brucella) and the biosafety recommended for handling and testing

Lessons Learned

• For example, if Gram-negative coccobacilli are seen on a Gram stain, Brucella and Francisella should be thought of, especially if the patient has compatible symptoms

Lessons Learned

• Poorly staining• Small gram-negative

coccobacilli (0.5-0.7 x 0.6-1.5 um)• Mostly seen as single

cells and appearing like "fine sand" CDC/PHIL

Brucella spp. Gram stain characteristics:

Lessons Learned

Brucella spp. colony characteristics:

CDC/PHIL

• Fastidious• Usually not visible at 24h• Grows slowly on most

standard laboratory media (e.g. SBA, choc and TSA)

• Pinpoint, smooth, entire translucent, non-hemolytic at 48h

BMBL

http://www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm

Pandemic/Avian Influenza Information

Appendix 4, from the HHS Pandemic Influenza Plan: “Laboratory Biosafety Guidelines for Handling and Processing Specimens or Isolates of Novel Influenza Strains”

Influenza testing

Pandemic Influenza Plans – HHS, DoD, State-specific, WHO, … .

• Commercial antigen detection testing for influenza may be conducted under BSL-2 containment conditions if a Class II biological safety cabinet is used

• Clinical specimens from suspected novel influenza cases may be tested by RT-PCR using standard BSL-2 work practices in a Class II biological safety cabinet for initial processing of patient specimens

Influenza testing (novel strains)

• If a specimen is confirmed positive for influenza A (H5N1) by RT-PCR, additional testing should be performed only under BSL-3 conditions with enhancements

• CDC’s Influenza Branch should be informed immediately by contacting the CDC Director’s Emergency Operations Center (DEOC) at 770-488-7100

Influenza testing (novel strains)

• All clinical labs can potential handle highly pathogenic organisms

• High emphasis must be placed on training and risk management

Lab Safety Summary

Questions?

Elizabeth A. Macias, Ph.D., D(ABMM)

Laboratory Director

Air Force Institute for Operational Health,

Epidemiological Surveillance Division (AFIOH/SDE)

2730 Louis Bauer Drive

Brooks City-Base, TX 78235-5132

COMM: 210.536.1271

DSN: 240.1271

Email: [email protected]

Documents

Laboratory Response Network Sentinel Laboratories Elizabeth A. Macias, Ph.D., D(ABMM)